Salts of Dasatinib in amorphous form

The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and sacchar...

Full description

Saved in:
Bibliographic Details
Main Authors Chiodo, Tiziana, Blatter, Fritz, Hintermann, Tobias, Siebenhaar, Bernd, Szelagiewicz, Martin, Salvador, Beate, Vossen, Marcus, Hafner, Andreas
Format Patent
LanguageEnglish
Published 23.03.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
Bibliography:Application Number: AU20140295143